Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Fractional COVID-19 Vaccine Boosters (MIACoV)
NCT05228730Phase 3Terminated
- Sponsor
- Murdoch Children's Research Institute
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozinameran, elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Murdoch Children's Research Institute. Started May 2022; status: terminated.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05228730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228730.